Skip to main content
Erschienen in: Clinical & Experimental Metastasis 8/2008

01.12.2008

Establishment and quantitative imaging of a 3D lung organotypic model of mammary tumor outgrowth

verfasst von: Michelle D. Martin, Barbara Fingleton, Conor C. Lynch, Sam Wells, J. Oliver McIntyre, David W. Piston, Lynn M. Matrisian

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

The lung is the second most common site of metastatic spread in breast cancer and experimental evidence has been provided in many systems for the importance of an organ-specific microenvironment in the development of metastasis. To better understand the interaction between tumor and host cells in this important secondary site, we have developed a 3D in vitro organotypic model of breast tumor metastatic growth in the lung. In our model, cells isolated from mouse lungs are placed in a collagen sponge to serve as a scaffold and co-cultured with a green fluorescent protein-labeled polyoma virus middle T antigen (PyVT) mammary tumor cell line. Analysis of the co-culture system was performed using flow cytometry to determine the relative constitution of the co-cultures over time. This analysis determined that the cultures consisted of viable lung and breast cancer cells over a 5-day period. Confocal microscopy was then used to perform live cell imaging of the co-cultures over time. Our studies determined that host lung cells influence the ability of tumor cells to grow, as the presence of lung parenchyma positively affected the proliferation of the mammary tumor cells in culture. In summary, we have developed a novel in vitro model of breast tumor cells in a common metastatic site that can be used to study tumor/host interactions in an important microenvironment.
Literatur
10.
Zurück zum Zitat Martin MD et al (2008) Effect of ablation or inhibition of stromal matrix metalloproteinase-9 lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 68:6251–6259 Martin MD et al (2008) Effect of ablation or inhibition of stromal matrix metalloproteinase-9 lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 68:6251–6259
11.
Zurück zum Zitat Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12(3):954–961PubMed Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12(3):954–961PubMed
12.
Zurück zum Zitat Liu M, Skinner SJ, Xu J et al (1992) Stimulation of fetal rat lung cell proliferation in vitro by mechanical stretch. Am J Physiol 263(3 Pt 1):L376–L383PubMed Liu M, Skinner SJ, Xu J et al (1992) Stimulation of fetal rat lung cell proliferation in vitro by mechanical stretch. Am J Physiol 263(3 Pt 1):L376–L383PubMed
14.
Zurück zum Zitat Mourgeon E, Isowa N, Keshavjee S et al (2000) Mechanical stretch stimulates macrophage inflammatory protein-2 secretion from fetal rat lung cells. Am J Physiol Lung Cell Mol Physiol 279(4):L699–L706PubMed Mourgeon E, Isowa N, Keshavjee S et al (2000) Mechanical stretch stimulates macrophage inflammatory protein-2 secretion from fetal rat lung cells. Am J Physiol Lung Cell Mol Physiol 279(4):L699–L706PubMed
16.
18.
Zurück zum Zitat Novaro V, Roskelley CD, Bissell MJ (2003) Collagen-IV and laminin-1 regulate estrogen receptor alpha expression and function in mouse mammary epithelial cells. J Cell Sci 116(Pt 14):2975–2986. doi:10.1242/jcs.00523 PubMedCrossRef Novaro V, Roskelley CD, Bissell MJ (2003) Collagen-IV and laminin-1 regulate estrogen receptor alpha expression and function in mouse mammary epithelial cells. J Cell Sci 116(Pt 14):2975–2986. doi:10.​1242/​jcs.​00523 PubMedCrossRef
20.
Zurück zum Zitat Ohmori T, Yang JL, Price JO et al (1998) Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp Cell Res 245(2):350–359. doi:10.1006/excr.1998.4261 PubMedCrossRef Ohmori T, Yang JL, Price JO et al (1998) Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp Cell Res 245(2):350–359. doi:10.​1006/​excr.​1998.​4261 PubMedCrossRef
Metadaten
Titel
Establishment and quantitative imaging of a 3D lung organotypic model of mammary tumor outgrowth
verfasst von
Michelle D. Martin
Barbara Fingleton
Conor C. Lynch
Sam Wells
J. Oliver McIntyre
David W. Piston
Lynn M. Matrisian
Publikationsdatum
01.12.2008
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 8/2008
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-008-9206-y

Weitere Artikel der Ausgabe 8/2008

Clinical & Experimental Metastasis 8/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.